Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

While similarities exist between types of alopecia, distinct clinical characteristics help patients & physicians ...

Experiencing hair fall is common, but excessive shedding signals underlying issues. Sudden hair loss, thinning, or bald spots ...

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

has granted Fast Track designation to bempikibart for the treatment of Alopecia Areata (AA), an autoimmune disease that attacks hair follicles causing patchy hair loss. Fast Track is a process ...

April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other ...

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.